Media OutReach

Media OutReach

Media OutReach

Uni-Bio Science Group and Kexing Biopharm Forge Strategic Partnership to Accelerate Global Expansion of Osteoporosis Treatment Bogutai®

Zhangqiu District, Jinan City, Shandong Province – September 2025 HONG KONG SAR – EQS Newswire – 12 September 2025 – Uni-Bio Science Group (“the Group”) is pleased to announce the signing of a strategic cooperation agreement with Kexing Biopharm (Stock Code: 688136.SH), a leading biopharmaceutical company with extensive expertise in global commercialization. Under this landmark agreement, Beijing Genetech Pharmaceutical Co., Ltd. (“Beijing Genetech”), a subsidiary of the Group, has granted Kexing Biopharm exclusive rights to commercialize Bogutai® (Teriparatide Injection) in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico (“Cooperation Regions”). Bogutai® is expected to complete registration and generate revenue in the Cooperation Regions as early as the end of 2026. The signing ceremony, held in Zhangqiu District, Jinan City, marks a pivotal step in the Group’s international expansion and its commitment to advancing osteoporosis care worldwide. Pioneering Osteoporosis Treatment with Proven Results Bogutai® is a recombinant human parathyroid hormone analog (PTH1–34), an anabolic treatment for osteoporosis that has been widely recognized for its efficacy and safety. Recommended by numerous domestic and international clinical guidelines, Teriparatide is particularly effective in improving bone microarchitecture and reducing fracture risk in postmenopausal women at high risk of fractures. Since its launch in China in March 2024, Bogutai® has demonstrated rapid market adoption, achieving a remarkable revenue growth of 248.9% year-on-year in the first half of 2025, reaching approximately HK$65.6 million. This impressive performance underscores the strong demand for innovative osteoporosis therapies and highlights the untapped potential of Bogutai® in global markets. Addressing the Global Osteoporosis Epidemic Osteoporosis, often referred to as a “silent killer,” affects over 200 million people globally, with the aging population exacerbating its prevalence. Early-stage osteoporosis is typically asymptomatic, leading to delayed diagnoses and severe complications such as fractures. In China, for example, only 6.5% of individuals receive osteoporosis treatment within six months of a fracture. Similarly, emerging markets across the Middle East and North Africa face low diagnosis and treatment rates despite growing awareness and significant patient populations. Injectable therapies like Teriparatide have been recommended by the Guidelines for Rational Drug Use of Osteoporosis in Primary Care (2021) for patients unable to tolerate oral medications, those with poor adherence, or individuals at high risk of fractures, including elderly patients with multiple vertebral or hip fractures. With its targeted mechanism of action as a bone-forming agent, Bogutai® is uniquely positioned to address this unmet medical need in both established and emerging markets. It is estimated that the osteoporosis market in the Cooperation Regions is nearly USD 1.5 billion, with a patient population exceeding 10 million. A Collaboration Built on Complementary Strengths Commenting on the partnership, Mr. Kingsley Leung, Chairman of Uni-Bio Science Group, said: “Teriparatide Injection is a transformative therapy with immense potential in overseas markets. By partnering with Kexing Biopharm, a company with a robust international commercialization network and proven operational expertise, we are confident in our ability to bring Bogutai® to patients in need across key regions. This collaboration represents a critical step in our mission to improve global bone health.” Mr. Zhao Yanqing, General Manager of Kexing Biopharm, added: “We are excited to join forces with Uni-Bio Science Group to unlock the regional potential of Bogutai®. With our established capabilities in regulatory approvals and market promotion, we aim to accelerate product registration and commercialization, ensuring that this innovative therapy reaches patients quickly and effectively.” Enhancing Global Competitiveness in Osteoporosis Care With over 20 years of international commercialization experience, Kexing Biopharm has built a strong marketing network spanning the European Union and emerging markets. The addition of Bogutai® to its portfolio complements its existing success with previously introduced denosumab injection, creating a comprehensive suite of osteoporosis treatments that combines “anti-resorptive” and “bone-forming” therapies. This synergy enhances the competitiveness of both companies in addressing the growing global demand for osteoporosis care. For Uni-Bio Science Group, this partnership is a key milestone in its internationalization strategy. Bogutai® is expected to generate revenue in the Cooperation Regions as early as the end of 2026, and with its competitive pricing, it may achieve higher profit margins. Beyond the collaboration with Kexing Biopharm, the Group is actively pursuing FDA approval for Bogutai® in the United States, having already received a waiver for in vivo bioequivalence studies. With this expedited regulatory pathway, FDA approval is anticipated in 2027, further solidifying the Group’s position as a leader in osteoporosis treatment. The Group is also advancing innovative pipeline products, including Uni-PTH (microneedle) for osteoporosis and UB107 (a Class III medical device) for bone repair, reinforcing its commitment to addressing unmet medical needs in bone metabolism and regenerative medicine. Shaping the Future of Osteoporosis Treatment Looking ahead, Uni-Bio Science Group remains dedicated to expanding its global footprint, deepening strategic partnerships, and accelerating the development of innovative therapies. By bringing Chinese innovation to the world, the Group aims to improve the lives of osteoporosis patients and set new standards in bone health and regenerative medicine. Hashtag: #UniBioScienceGroup The issuer is solely responsible for the content of this announcement. About Bogutai® (Teriparatide Injection) Bogutai® (Teriparatide Injection) is a biologically expressed recombinant human parathyroid hormone analog (PTH1–34), representing the active 34-amino-acid N-terminal region of the full 84-amino-acid human parathyroid hormone. This advanced therapeutic agent is specifically indicated for postmenopausal women with osteoporosis who are at high risk of fractures. Bogutai® exerts its effects by stimulating osteoblast activity, promoting new bone formation, and increasing bone mineral density (BMD). Unlike antiresorptive therapies that primarily inhibit bone resorption, Bogutai® actively enhances bone remodeling by increasing osteoblast-mediated bone deposition while indirectly regulating osteoclast activity to maintain a balanced bone turnover. This anabolic mechanism makes it a highly effective treatment option for reducing the risk of fractures and improving skeletal integrity in patients with severe osteoporosis. About Uni-Bio Science Group Uni-Bio Science Group Limited (Stock Code: HK 00690) is a biopharmaceutical company dedicated to utilizing new synthetic biology technology to develop next generation regenerative therapies in the orthopedics, ophthalmology, dermatology and medical aesthetics. The Group also has three GMP manufacturing bases

Media OutReach

Appier Drives GenAI-Powered Creatives Transformation with AdCreative.ai, Empowering Hong Kong Brands to Accelerate into the Agentic AI Marketing Era

HONG KONG SAR – Media OutReach Newswire – 12 September 2025 – Appier (TSE: 4180), an AI-native SaaS company specializing in AdTech and MarTech solutions, today hosted the GenAI for Marketing Asia Pacific roadshow in Hong Kong, demonstrating how its Generative AI-powered creative platform AdCreative.ai is helping local brands scale creativity, reduce costs and drive measurable performance, alongside its Agentic AI solutions designed for marketers. Appier CEO and co-founder Chih-Han Yu at the GenAI for Marketing Asia Pacific roadshow in Hong Kong. AdCreative.ai enables brands to generate commercial videos, images, and interactive ad assets quickly and at scale. It also integrates Appier’s seven upgraded AI Agents—Coding Agent, Director Agent, Sales Agent, Campaign Agent, Service Agent, Audience Agent, and Insight Agent, delivering data-driven insights and performance predictions that help marketers achieve scalable, ROI-driven marketing with greater speed, intelligence, and efficiency. The event drew over 100 marketers and advertisers from leading brands and agencies to explore the future of AI-driven marketing. Recent research underscores the momentum. According to McKinsey, 78% of companies have already deployed AI in at least one business function, with marketing among the top. BCG projects that more than 90% of companies in APAC are planning to scale up GenAI over two years, citing its ability to cut costs and accelerate revenue growth. With its role as an innovation hub, Hong Kong provides fertile ground for brands to experiment, adopt and scale AI solutions. “Fast-changing consumer markets are placing new demands on Hong Kong brands, particularly in balancing creativity with global expansion,” said Apple Chu, Head of Ad Cloud Sales, Hong Kong, Appier. “High-performing creatives are traditionally costly and time-consuming to produce. AdCreative.ai streamlines this process, delivering diverse formats such as product videos, UGC, and playable ads with compliance checks and performance predictions, becoming a true growth engine for brands.” “AdCreative.ai’s creative power, combined with Appier’s enterprise Agentic AI solutions’ strengths in data integration, predictive analytics and personalized engagement, is opening a new chapter in data-driven creative marketing,” added Allen Chen, Senior Director of Enterprise Solutions Sales, Greater China, Appier,“ We are enabling Hong Kong brands to understand user behavior, achieve smarter segmentation and activate real-time insights, powering personalized, scalable workflows that improve ROI and keep brands ahead in today’s dynamic market.” Hong Kong Brands Already Benefiting Several leading Hong Kong brands have already embraced AdCreative.ai with measurable success: Future Salad, founded in 2020, is a Hong Kong food-tech company expanding into the overseas market. To address resource limits in producing large volumes of product launch videos to test audience reactions, it adopted AdCreative.ai to overcome filming location restrictions and ensure brand-consistent assets with accurate logo placement. Results exceeded other AI tools: CTR rose 82%, CPC fell 35%, CVR improved 71%, and ROAS surged 143%, making it a key driver of Future Salad’s AI marketing transformation. Lukfook Jewellery established its first shop in Hong Kong in 1991, marking over thirty years of history. As a brand under Lukfook Group (0590), a listed company on the Main Board of the Hong Kong Stock Exchange, Lukfook Jewellery has earned the trust and admiration of customers through its strong brand reputation, product quality, and commitment to its “Six Heartfelt Services” service standard. AdCreative.ai helps Lukfook preserve jewelry ad aesthetics, cut costly manual workflows, quickly generate diverse creatives, and accelerate AI-enabled e-commerce marketing transformation. The Korner, founded in 2015, is a Hong Kong footwear brand blending elegance and comfort, with over 20 stores. For its Snoopy collaboration, it used AdCreative.ai to generate commercial videos. Traditional production took 3–4 weeks and heavy resources across social, ad platforms, EDMs, and in-store displays. With AdCreative.ai, videos were produced in hours, personalized to audience preferences, enabling scalable customization, reducing design time, improving ROAS, and doubling video views versus similar campaigns. As marketing enters a new era, Appier is building on more than a decade of AI expertise to empower brands. Through its AI product suite—Ad Cloud, Personalization Cloud and Data Cloud, Appier delivers Autonomous, Adaptive and Agentic AI solutions that span the entire customer journey, from audience insights and omnichannel marketing to creative generation. Appier remains committed to helping brands turn AI into ROI, equipping Hong Kong enterprises to stay agile and competitive in the Agentic AI era. Hashtag: #AI #AgenticAI #GenAI #MarTech #AdTech #Appier https://www.appier.com/en/https://www.linkedin.com/company/2774891/https://www.facebook.com/appierinc?locale=zh_TWWechat: Appier 沛星互动科技 The issuer is solely responsible for the content of this announcement. About Appier Appier (TSE: 4180) is an AI-native SaaS company that empowers businesses to create value through cutting-edge AdTech and MarTech solutions. Founded in 2012 with the vision of “Making AI Easy by Making Software Intelligent,” Appier helps businesses turn AI into ROI through its Ad Cloud, Personalization Cloud, and Data Cloud—each powered by Agentic AI that enables autonomous, adaptive, and real-time decision-making. Today, Appier operates 17 offices across APAC, the US, and EMEA, and is listed on the Tokyo Stock Exchange. Learn more at www.appier.com.

Media OutReach

FGA Trust Showcases Hong Kong’s Institutional Strength at 2025 Inclusion Conference on the Bund

HONG KONG SAR – Media OutReach Newswire – 12 September 2025 – FGA Trust, a licensed trustee in Hong Kong, participated in the 2025 Inclusion Conference on the Bund by the invitation of InvestHK, and underscored the city’s role as a bridge between global capital flows and Asia’s fast-growing digital asset landscape. The firm’s participation highlighted the synergy between Hong Kong’s regulatory innovation and China’s financial opening, which is reshaping the future of cross-border wealth management. Trust Structures Support Diversified Allocation As global high-net-worth migration accelerates, demand for institutional-grade wealth management frameworks continues to rise. According to the Hong Kong Securities and Futures Commission (2024), the city’s trust market—anchored by approximately HK$1.45 trillion in assets linked to family offices and private clients—is evolving beyond its traditional focus on succession and tax planning toward broader asset allocation. At the conference, FGA Trust emphasized its ability to help international families diversify across equities, bonds, real estate, and the rapidly expanding digital asset class, all within a transparent and compliant framework. RWA Regulation at the Center of Discussion FGA Trust CSO Helen Chen at the Inclusion Conference. During the policy discussion, Helen Chen, Chief Strategy Officer of FGA Trust, shared insights on Hong Kong’s RWA regulatory sandbox, stressing how the framework enables innovation while balancing risk management in a controlled pilot environment. She noted that Hong Kong’s regulatory design is shifting from a static framework to an evolving testing platform, offering new opportunities for wealth managers and trustees to integrate digital assets. Synergy Between Hong Kong and Shanghai The Bund Conference further highlighted the complementary roles of Hong Kong and Shanghai in wealth management. For Chinese entrepreneurs and family offices, Hong Kong’s trust and cross-border frameworks provide internationalization channels, while Shanghai represents a vast onshore capital base. FGA Trust leveraged the event to engage with mainland investors, showcasing its AI-driven onboarding processes, asset-linked trust solutions, and hybrid wealth structures designed to bridge the two markets. Through its presence at the Bund Conference, FGA Trust not only showcased Hong Kong’s strengths in global capital migration, regulatory innovation, and digital asset adoption, but also underscored the evolving mission of the trust industry: to transform from a static asset container into a dynamic platform integrating traditional and digital wealth management. Hashtag: #FGATrust The issuer is solely responsible for the content of this announcement.

Media OutReach

eefit Far Infrared Technology Scientifically Verified by Renowned Hong Kong University: Improves Two Major Symptoms of Alzheimer’s Disease, Bringing New Hope to Brain Health Protection

HONG KONG SAR – Media OutReach Newswire – 12 September 2025 – With Hong Kong’s aging population, Alzheimer’s disease has become a major public health challenge. The Hong Kong Council of Social Service projects that by 2036, the number of people with dementia in Hong Kong will reach 280,000. Alzheimer’s disease is the most common form of the condition, accounting for approximately 65% of existing cases among elderly individuals. A recent report released by the Dean of the Faculty of Chinese Medicine at a renowned Hong Kong university stated, “Considerable resources have been invested globally in developing treatments for Alzheimer’s disease. However, for patients in the middle and late stages of the disease, various treatment options remain ineffective in halting the progression of the disease.” These treatments not only have limited effectiveness but also come with side effects, creating an increasingly urgent need for disease prevention and treatment. In 2025, the collaboration between the research team of that leading university in Hong Kong and Prof. Nick Wang, Founder and Head of R&D at eefit has led to a critical breakthrough. They discovered that eefit far infrared technology can simultaneously suppress β-amyloid (Aβ) deposition and tau protein hyperphosphorylation, creating an innovative solution for preventing Alzheimer’s disease. The results were published in NeuroMolecular Medicine (Volume 27, Article 34, 2025). First Study with Evidence of Simultaneous Dual-Pathology Improvement Mechanism in Transgenic Mouse Model To address the future need for Alzheimer’s disease prevention and treatment in Hong Kong, the research team explored non-pharmacological physical therapies. Using a TgCRND8 transgenic mouse model, they conducted a 28-day irradiation experiment with eefit far infrared light (FIR, wavelength range of 4-20μm) to evaluate its effectiveness in improving disease pathology. The study found: Improved cognitive function: The FIR-treated mice group showed significant improvement in cognitive function and memory during the Morris Water Maze Test (MWMT). Aβ deposition suppression: Decreased Aβ42/Aβ40 ratio in the cortex, reduced plaque deposits, and increased Aβ clearance. Tau protein hyperphosphorylation inhibition: Significantly reduced tau protein phosphorylation levels at different sites, such as Thr205, Ser36, etc., and reduced the formation of neurofibrillary tangles. Dual-pathway mechanism: Suppression of neuroinflammatory pathways (reduced IL-1β, TNF-α and increased IL-4) and activation of antioxidant pathways (enhanced Nrf2/HO-1 pathway), achieving dual-pathway protection. Using a transgenic mouse model, this study confirms for the first time that eefit far infrared technology can simultaneously reduce Aβ deposition and tau protein hyperphosphorylation through physical intervention. Previous studies have only focused on single-pathology interventions, making the significance of this study on the dual-pathway improvement effect groundbreaking. The Dean of the Faculty of Chinese Medicine at a renowned Hong Kong university said, “As a non-invasive treatment option, far infrared therapy has the potential to delay the disease progression of patients with mild cognitive impairment for several years, thereby reducing the burden on overall medical resources and providing significant assistance to families and caregivers.” This groundbreaking discovery also provides solid scientific evidence to support the industrial application of eefit far infrared technology. International R&D Team Drives Industrialisation Capability To promote the transformation of far infrared technology from scientific research results to industrial applications, eefit has built a global R&D system with scientific research as its core driving force, first collaborating with the “State Key Laboratory of Quality Research in Chinese Medicine” at the Macau University of Science and Technology (M.U.S.T.) to launch the “eefit Biomedical Research Project” in the early years. In 2021, eefit further expanded its global collaboration network by partnering with “Dr. Neher’s Biophysics Laboratory for Innovative Drug Discovery”, founded by Dr. Erwin Neher, Nobel Prize Laureate in Physiology or Medicine, strengthening its R&D capability. In recent years, multiple international journal articles have confirmed that eefit far infrared technology is effective in the fields of intestinal microecology, rheumatoid arthritis, cerebral stroke, neuroinflammation, and immunomodulation. Market Response and Social Responsibility Are Equally Important In tandem with advancing scientific research, eefit is also dedicated to upholding our social responsibilities. In 2024, eefit launched the “eBrain Movement”, which provided brain health services to 212,000 people across our retail stores in Hong Kong. User feedback showed improvement in their bodily conditions, including neurodegenerative symptoms such as headaches, tinnitus, hair loss, hand tremors, nocturia, etc., with unanimous reports of improved sleep quality after treatment. Both this programme and academic research have proven the remarkable effect of eefit far infrared technology in the fields of brain health, sub-health of the middle-aged and elderly, and auxiliary treatment of complex diseases. Multidimensional Breakthrough in Managing Sub-Health in the Middle-Aged and Elderly​ Based on this technology, eefit has already developed a variety of products, building an all-encompassing “Prevention + Maintenance + Adjustment” health management system, meeting the diverse needs of the middle-aged and elderly population from disease prevention to daily health management: Alzheimer’s disease prevention: Reduces Aβ deposits and abnormal tau proteins, reducing the risk of disease. Brain health: Relieves neurological problems such as effects of stroke, and enhances brain vitality. Chronic pain care: Relieves pains such as neck/shoulder/lower back/leg pain, and rheumatoid arthritis, etc. Digestive system regulation: Optimizes gut microbiota and enhances nutrient absorption. The issuer is solely responsible for the content of this announcement. About eefit Based in Hong Kong, eefit has services available throughout the city. With leading service coverage and an innovative product matrix, we provide customers with convenient and efficient health management solutions. This Alzheimer’s disease pathology improvement study further verifies that eefit far infrared technology can put scientific research into practice in daily life. eefit is committed to ongoing investment in technological R&D to propel the advancement and innovation in health technology. Contact email: [email protected] Company website: https://bit.ly/45UoKSG Facebook page: Facebook.com/eefit

Media OutReach

Hainan Free Trade Port Tourism Promotion: Embracing Warm Sunshine

HONG KONG SAR – Media OutReach Newswire – 12 September 2025 – As September ushers in seasonal changes across many regions worldwide, Hainan Free Trade Port has kicked off a series of tourism promotion activities in Hong Kong, south China. These events include a themed conference, a tourism photo exhibition, an intangible cultural heritage exhibition, and a Li brocade fashion show, all designed to highlight the unique allure of the tropical island province to Hong Kong citizens and global tourists. Hainan Free Trade Port Tourism Promotion: Embracing Warm Sunshine The 5-day activities started on Sept. 7, hosted by the Hainan Department of Tourism, Culture, Radio, TV, and Sports, and other authorities. During the “All the Sun, All the Fun” Hainan Free Trade Port Tourism Promotion Conference, nearly 100 guests from various organizations, including the Asian Tourism Exchange Center, Hong Kong Tourism Commission, Hong Kong Tourism Board, Hong Kong Federation of Hainan Community Organizations, City University of Hong Kong, and several travel operators, were invited to experience the island’s charm during this season of pleasant weather. Tommy Tan, chairman of the Travel Industry Council of Hong Kong, stated that Hainan boasts abundant tourism resources, while Hong Kong is a world-class international financial center and a hub for cultural and artistic exchange. The two places can enjoy complementary and synergistic effects. The integration of Hainan’s resources and Hong Kong’s platforms is a solid foundation for successful cooperation. The tourism photo exhibition has become a major highlight of the promotional activities. Featuring over 80 stunning photographs, it showcases the most beautiful moments of Hainan’s ten major tourism products (e.g., ocean, health, and aerospace). Hong Kong citizen Huang Wenhua said, “I haven’t been to Hainan yet, but after seeing these pictures, I suddenly feel a strong urge to visit!” The event also featured Hainan’s intangible cultural heritage, ethnic costumes, cultural performances, and local specialties, all of which captivated visitors. In particular, the Li brocade clothing, with a history spanning 3,000 years, stood out prominently against the stylish backdrop of Hong Kong’s fashion scene. Tang Qiuchen, an executive of Hainan Li Brocade Culture Communication Co., Ltd., expressed, “The Li people record their culture through the patterns on their brocade. The beauty of Hainan is not only reflected in the blue sky and clear sea but also in these cultural items.” During the event, the Hainan Department of Tourism, Culture, Radio, TV, and Sports awarded “Tourism International Promotion Ambassador” certificates to six Hong Kong social media influencers. One of the recipients, Lin Lijun, said that Hainan is a place worth exploring. She looks forward to using her camera to share the experience of the gentle sea breeze, warm sunshine, and the relaxed pace of life with her followers. Hashtag: #Hainan The issuer is solely responsible for the content of this announcement.

Media OutReach

KPLASS Recognised at Osaka World Expo 2025 for Breakthrough Far-Infrared Cough Relief Patch

Develops Far-Infrared patches supporting natural and non-invasive wellness. KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 12 September 2025 – KPLASS, a manufacturer and brand of Far Infrared Technology patches, has received several awards at the Osaka World Expo 2025 namely the “Special Honour Product”, “Innovative Product Award”, “Distinguished Manufacturer Award” and “Outstanding Contribution Award”. Its Far Infrared Cough Relief Patch is available to consumers across Southeast Asia, including Malaysia, Singapore, Vietnam, Cambodia, and other markets. This recognition marks a notable milestone as KPLASS continues to expand in the region. The KPLASS Far Infrared Cough Relief Patch uses Far Infrared Technology combined with targeted acupoint stimulation. Unlike conventional heat pads that provide surface warmth, Far Infrared rays penetrate deeper layers of the skin and help in blood circulation and other bodily functions. When applied to acupoints such as TianTu and DanZhong, the patch is activated to emit gentle heat through the acupoints that could improve blood flow, reduce inflammation and provide relief from cough symptoms through a non-invasive method. “This recognition at the Osaka World Expo highlights our ongoing efforts in health and wellness innovation. By combining Far Infrared Technology with acupoint therapy, we aim to offer patches that are safe and effective for a wide range of users. We continue to focus on broadening access across Asia Pacific.” said Michael Hu, Founder and CEO of KPLASS Singapore. The KPLASS range includes the Far Infrared Adult Cough Relief Patch, as well as a Far Infrared Child Cough Relief Patch intended for children aged 3 months to 6 years. Additional products in the range target pain relief, joint pain relief, and menstrual relief. These patches are designed to complement the body’s natural processes and provide non-invasive support. KPLASS’s regional presence is growing in response to increased consumer interest in natural and technology-assisted health products, particularly in Malaysia. Plans are currently underway to introduce the Child Cough Relief Patch to the Malaysian market, complementing the existing adult range already available nationwide. In Singapore, KPLASS was named “Best Selling Cough Patch” by Watsons in 2022, 2024, and 2025, while the Child Cough Relief Patch continues to gain traction. KPLASS relief patches are available in Malaysia at Watsons, Guardian, Alpro, AA Pharmacy, Multicare, Healthlane, Pillbox stores and other pharmacies nationwide. For more information, please visit www.kplass.sg, or follow KPLASS on Instagram and Facebook for the latest updates. Image can be downloaded from this link – [Click Here]. Hashtag: #KPLASS #FarInfrared #Technology #Health http://www.kplass.sghttps://www.facebook.com/kplassmalaysia/?ref=_xav_ig_profile_page_webhttps://www.instagram.com/kplass_malaysia/ The issuer is solely responsible for the content of this announcement. About KPLASS KPLASS is a Singapore brand using leading edge of technology and healthcare innovation to alleviate daily body discomforts. It uses the Far Infrared technology, which is natural, safe and effective that helps to relieve the cough symptoms and various body pains. Backed by 25 years of R&D and manufacturing competency of its parent company, the marketing and offering are differentiated by combined Infrared technology and TCM Acupoints in everyday health care solutions that is drug free, non-invasive and thus convenient and user-friendly. Bring home the Infrared treatment at your comfort and convenience.

Media OutReach

Global Report puts Evidence as Heart of Better Philanthropy to Tackle Complexity

Tanoto Foundation presents findings at AVPN Global Conference HONG KONG SAR – Media OutReach Newswire – 12 September 2025 – At a time when governments, development agencies, and NGOs strive to address complex social challenges, the necessity to demonstrate real, sustainable results has never been greater. To remain effective, philanthropy must move with purpose, not only to fund initiatives but also to embrace measurement and evidence as a compass for decision-making and meaningful social change. To help the philanthropic sector do good, better, Tanoto Foundation launched The Evidence Behind Better Philanthropy report at the AVPN Global Conference in Hong Kong. The study, developed in partnership with the Centre for Evidence and Implementation (CEI), provides a first-of-its-kind comparative analysis of how leading global foundations practice monitoring, evaluation, and learning (MEL), a much-discussed but often elusive cornerstone of effective philanthropy. By combining in-depth interviews with foundation leaders and an extensive review of global practice, the report offers timely insights from some of the world’s most influential funders on how evidence is shaping strategy, guiding adaptation, and enabling more collaborative approaches to impact across diverse and complex contexts. Benny Lee, CEO of Tanoto Foundation, said: “For philanthropy to do good, it must also do better, because today’s challenges are more complex and interconnected. At Tanoto Foundation, we see evidence not just as a tool for accountability, but as a compass for strategy. By embedding monitoring, evaluation, and learning at the heart of decision-making, we can steward resources more effectively and contribute to meaningful, lasting social change.” The report identifies 10 key findings, clustered into three broad themes for the philanthropic sector: 1. Strategy and Decision-Making: Embedding evidence into strategy through integrated “SMEL” (Strategy, Monitoring, Evaluation, and Learning) ensures programmes are responsive and adaptive, reducing wasted resources and increasing policy effectiveness. 2. Culture and Capacity: A learning culture, backed by senior leadership and grantee capacity-building, enables funders and implementers to course-correct in real time – critical for large-scale reforms and systems change. 3. Tools and Ecosystem for Impact: Flexible evaluation methods, a focus on contribution over attribution, and strategic communication help funders, governments, and NGOs align their efforts and scale what works. Murni Leo, Global Head of Measurement, Learning and Evaluation at Tanoto Foundation, added: “This study reflects our belief that learning should not stop at compliance, but drive continuous improvement. At Tanoto Foundation, we have embedded MEL into how we design programmes, test assumptions, and adapt in real time. By sharing global practices openly, we hope to encourage a culture of collaboration where funders and partners alike can strengthen their use of evidence. When the sea rises, all boats rise—and MEL is one way to lift the sector together.” The report aims to support decision-makers across sectors to design more effective interventions, strengthen accountability, and collaborate for systemic change. The full report is now available and can be downloaded via the Tanoto Foundation website. Hashtag: #TanotoFoundation The issuer is solely responsible for the content of this announcement. About Tanoto Foundation At Tanoto Foundation, we unlock human potential, help communities thrive, and create lasting impact. Founded in 1981 by Sukanto Tanoto and Tinah Bingei Tanoto, we are an independent family foundation that believes in providing every person with the opportunity to realize his or her full potential. To do so, we catalyse systems change in education and healthcare. Our approach is impact-first, collaborative, and evidence-based. We invest for the long term and strive to develop leaders who can drive sustained, positive outcomes. More information is available at www.tanotofoundation.org/en/

Media OutReach

KPLASS Singapore Awarded at Osaka World Expo 2025 for Innovation in Far-Infrared Cough Relief Patch

Develops Far-Infrared patches supporting natural and non-invasive wellness. SINGAPORE – Media OutReach Newswire – 12 September 2025 – KPLASS, a manufacturer and brand of Far Infrared Technology patches, has received has received several awards at the Osaka World Expo 2025 namely the “Special Honour Product”, “Innovative Product Award”, “Distinguished Manufacturer Award” and “Outstanding Contribution Award”. Its Far Infrared Cough Relief Patch is available to consumers across Southeast Asia, including Malaysia, Singapore, Vietnam, Cambodia, and other markets. This recognition marks a notable milestone as KPLASS continues to expand in the region. KPLASS Recognised at Osaka World Expo 2025 for Breakthrough Far-Infrared Cough Relief Patch The KPLASS Far Infrared Cough Relief Patch uses Far Infrared Technology combined with targeted acupoint stimulation. Unlike conventional heat pads that provide surface warmth, Far Infrared rays penetrate deeper layers of the skin and help in blood circulation and other bodily functions. When applied to acupoints such as TianTu and DanZhong, the patch is activated to emit gentle heat through the acupoints that could improve blood flow, reduce inflammation and provide relief from cough symptoms through a non-invasive method. “This recognition at the Osaka World Expo highlights our ongoing efforts in health and wellness innovation. By combining Far Infrared Technology with acupoint therapy, we aim to offer patches that are safe and effective for a wide range of users. We continue to focus on broadening access across Asia Pacific.” said Michael Hu, Founder and CEO of KPLASS Singapore. The KPLASS range includes the Far Infrared Adult Cough Relief Patch as well as the Far Infrared Child Cough Relief Patch, designed for children aged 3 months to 6 years. Safe for both adults and young children, the patch offers a gentle yet effective alternative to traditional medication, suitable for use during the day or night. Additional products in the range target pain relief, joint pain relief, and menstrual relief, with each relief patch developed to work naturally with the body through a non-invasive approach. KPLASS’s regional presence is growing in response to increased consumer interest in natural and technology-assisted health products. In Singapore, KPLASS was named “Best Selling Cough Patch” by Watsons in 2022, 2024, and 2025, with the Child Cough Relief Patch gaining steady traction among parents seeking safe, drug-free options for their families. KPLASS relief patches are available at leading pharmacy chain like Guardian, Watsons and Unity and also online via Shopee and Lazada in Singapore. For more information, please visit www.kplass.sg, or follow KPLASS on Instagram and Facebook for the latest updates. Hashtag: #KPLASS #FarInfrared #Technology #Health http://www.kplass.sghttps://www.facebook.com/KplassSingaporehttps://www.instagram.com/kplass_singapore/ The issuer is solely responsible for the content of this announcement. About KPLASS KPLASS is a Singapore brand using leading edge of technology and healthcare innovation to alleviate daily body discomforts. It uses the Far Infrared technology, which is natural, safe and effective that helps to relieve the cough symptoms and various body pains. Backed by 25 years of R&D and manufacturing competency of its parent company, the marketing and offering are differentiated by combined Infrared technology and TCM Acupoints in everyday health care solutions that is drug free, non-invasive and thus convenient and user-friendly. Bring home the Infrared treatment at your comfort and convenience.

Media OutReach

Creature Comforts Veterinary Group opens Hong Kong Island’s first purpose-built Fear Free® 24-hour animal hospital

East Island 24-Hour Animal Hospital spans 11,000 sq ft across two floors, offering Fear Free® design, advanced medicine, and affordable premium care with extended consultation hours. HONG KONG SAR – Media OutReach Newswire – 12 September 2025 – Creature Comforts Veterinary Group, with over 23 years of history in Hong Kong, proudly introduces the East Island 24-Hour Animal Hospital in Shau Kei Wan. Spanning 11,000 square feet across two floors, it is Hong Kong Island’s first veterinary hospital purpose-built around Fear Free® principles. East Island 24 Hours Animal Hospital The facility offers a calming environment with dog-and-cat separation, soundproof feline wards, Rainbow Rooms for sensitive moments, and family lounges. Families can also access extended consultations until midnight, with seamless 24/7 emergency support. Behind the design lies advanced medical capability: real-time ICU monitoring, a dedicated blood bank with guaranteed delivery, laser therapy, a three-times larger isolation ward and expanded diagnostics (ultrasound, echocardiography, endoscopy). A CT scanner and a mobility-friendly animal lift will be added later this year. “High-quality veterinary medicine should not be limited to a select few. Premium care doesn’t need to come with premium pricing,” said Dr David, Medical Director. “When animals are calm, they recover better. And when owners feel safe, they can focus on supporting their pets rather than panicking,” added Dr Kaylen, Vet Manager. The hospital is also actively developing charity give-back projects, such as Adoption Day events with Paws United Charity, to support the community and promote pet adoption. For Creature Comforts, which began in 2002 as Hong Kong’s first house-call vet service, expanded with the Veterinary TKO Center in 2021, and now cares for more than 40,000 pets across the city, the new hospital is both a milestone and a promise: Fear Free®, advanced, and accessible care for every family. Media enquiries & access: Exclusive hospital tour and photo/video opportunities are available upon request. Hashtag: #CreatureComforts #24hoursAnimalHospital #FearFreeCare #AffordablePremiumCare #HKPets https://www.creaturecomforts.com.hk/en-twhttps://www.linkedin.com/company/creature-comforts-group/https://www.facebook.com/creaturecomfortshk/https://www.instagram.com/creaturecomfortshk/?hl=en The issuer is solely responsible for the content of this announcement. Creature Comforts Veterinary Group Creature Comforts has been serving Hong Kong pet families for over 23 years, beginning in 2002 as the city’s first house-call veterinary service and expanding with the Veterinary TKO Center in 2021. Today, the Group cares for more than 40,000 pets across the city. Its mission remains the same: to deliver Fear Free®, professional and compassionate veterinary care that is both high-quality and affordable.

Media OutReach

Hong Kong Lab Zentrogene Cracks Twin DNA Code; Gender Mystery Solved for Moms Worldwide

HONG KONG SAR – Media OutReach Newswire – 12 September 2025 – Zentrogene Laboratory, an international genetic testing institution based in Hong Kong (under Sanai Health Industry Group 01889.HK), announced the launch of its ‘Y Precision’ testing technology based on Next-Generation Sequencing (NGS). This locally developed innovation in Hong Kong addresses longstanding industry challenges in gender determination for twin pregnancies. It overcomes the limitations of traditional qPCR platforms, achieving the first-ever precise identification of male-female twins while significantly enhancing the accuracy of fetal cell-free DNA (cfDNA) analysis. Illustration: IP Image Ambassador Dr.z Traditional methods could only qualitatively detect the presence of the Y chromosome, failing to distinguish between male-male twins and male-female twins. They also lacked the capability to identify residual male cfDNA after fetal reduction procedures. Zentrogene’s NGS-based technology achieves three breakthroughs: Fetal Signal Assessment: Utilizes whole-genome SNP scanning to confirm fetal signal presence, precisely quantify fetal fraction, and determine the number of fetal signals. Contamination Identification: Differentiates between false signals (e.g., contamination-derived Y chromosome fragments) and true fetal signals. Twin Pregnancy Precision Analysis: Independently analyzes X and Y chromosome fragments to accurately distinguish male-female twins from male-male twins. As a pioneer in Hong Kong’s genetic testing field, Zentrogene has established a global technology matrix covering pre-pregnancy, prenatal, and oncology applications through its integrated Sanger sequencing and NGS platforms. This NGS breakthrough underscores its ‘Technology-Driven Globalization’ strategy, leveraging Hong Kong’s expertise to deliver precision medical solutions worldwide. Zentrogene continues to advance genetic technology, safeguarding every family’s hopes with scientific rigor. For details, visit: https://www.zentrogene.com/ https://www.zentrogene.com.hk/ Official Cooperation Contacts: Telephone: +86 18051865085 (WeChat same number) Telegram: +855 99990026 Facebook: Zentrogene Hashtag: #Zentrogene The issuer is solely responsible for the content of this announcement.

Scroll to Top

Subscribe
FREE Newsletter